Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,118
  • Shares Outstanding, K 96,398
  • Annual Sales, $ 10,650 K
  • Annual Income, $ -45,440 K
  • 60-Month Beta 2.69
  • Price/Sales 7.18
  • Price/Cash Flow N/A
  • Price/Book 1.30
Trade CRIS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings -0.14 on 11/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -412.31%)
  • Historical Volatility 65.28%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,326.95% on 11/10/22
  • IV Low 0.00% on 12/02/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 40
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 34,082
  • Open Int (30-Day) 33,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.14
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7110 +12.52%
on 11/09/22
0.9296 -13.94%
on 11/15/22
-0.0612 (-7.11%)
since 11/02/22
3-Month
0.6800 +17.65%
on 09/28/22
1.0350 -22.71%
on 09/09/22
-0.1053 (-11.63%)
since 09/02/22
52-Week
0.6800 +17.65%
on 09/28/22
5.2700 -84.82%
on 01/05/22
-3.9700 (-83.23%)
since 12/02/21

Most Recent Stories

More News
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 0.8000 (+0.88%)
BFRI : 1.0500 (-0.09%)
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 0.8000 (+0.88%)
Curis Provides Third Quarter 2022 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 0.8000 (+0.88%)
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.97 (+12.50%)
CRIS : 0.8000 (+0.88%)
Curis Announces Three Presentations at SITC 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 0.8000 (+0.88%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 0.8000 (+0.88%)
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 0.8000 (+0.88%)
Curis Announces Date for the 2nd Annual VISTA Symposium

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 0.8000 (+0.88%)
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic...

JNJ : 178.88 (+0.08%)
CRIS : 0.8000 (+0.88%)
ABBV : 163.66 (+1.26%)
ACHL : 1.7500 (unch)
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

JNJ : 178.88 (+0.08%)
CRIS : 0.8000 (+0.88%)
ABBV : 163.66 (+1.26%)
IMVT : 14.68 (+5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 0.8800
2nd Resistance Point 0.8500
1st Resistance Point 0.8250
Last Price 0.8000
1st Support Level 0.7700
2nd Support Level 0.7400
3rd Support Level 0.7150

See More

52-Week High 5.2700
Fibonacci 61.8% 3.5166
Fibonacci 50% 2.9750
Fibonacci 38.2% 2.4334
Last Price 0.8000
52-Week Low 0.6800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar